Advanced Business Development Course 2013

November 1–3, 2013
Hilton Vienna Danube
Vienna, Austria

Attendance is limited to 75 participants to ensure the optimal instructor/student ratio and quality interaction.

Take your skills to the next level by working directly with colleagues in a hands-on, practical course that uses a realistic business case!

The Advanced Business Development Course is designed for business development professionals interested in bringing their skills in valuation, due diligence, negotiation and contracts to the next level. During this intensive, three-day session attendees will receive advanced hands-on training from veteran business development professionals and legal advisers using real-world case studies. Delegates will work in teams to successfully negotiate a term sheet for a clinical stage compound.

This course has been organized for life science business development professionals by the Biotechnology Industry Organization in collaboration with EBD Group. The faculty is drawn from among the most experienced business development professionals in the biotech drug development industry as well as big pharma, many of whom have been instructors in other programs, and all of whom have extensive experience in the biotech industry.

The course will cover basic topics and skills crucial to every business development professional in the industry, including:

• Valuation skills
• Intellectual property
• Due diligence
• Negotiation and influence strategies
• Contracts in depth

Who should attend?
Although this course is recommended for business development professionals with approximately 3–5 years experience, it is highly recommended to ambitious individuals with demanding business development and senior management goals. It is designed for business development professionals who have most likely served as part of a business development or licensing team, but are now preparing to move to a senior manager role within their organization.

• Business development and licensing professionals
• Alliance management professionals
• R&D personnel who have significant interaction with business development
• Intellectual property personnel involved in the licensing process
• Biotech company CEOs

Attendance is limited to 75 participants to ensure the optimal instructor/student ratio and quality interaction.

And stay for the BIO-Europe® 2013 international partnering conference, which starts immediately after this course finishes.